Cipher Pharmaceuticals Inc.
TSX:CPH.TODrug Manufacturers - Specialty & Generic
+$0.15 today
- Market cap
- $331.67M
- Beta
- 0.48
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.22
Volume 0.04M
Average 0.03M
CPH.TO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Cipher Pharmaceuticals Inc.TSX: CPH.TO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $304K rose 24.6% year over year, behind the +64.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 42.1% from the prior quarter. Over 3 fiscal years it compounded at +62.8% a year.
Context
- Stock-based compensation amounted to 3.4% of revenue in FY2025, up 0.2 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +24.6% toward the trailing-twelve-month pace of +64.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.74M USD
- Year-over-year change
- +62.1%
- 4-year CAGR
- +88.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.74M | +62.1% |
| FY2024 | 2024-12-31 | 1.07M | -9.9% |
| FY2023 | 2023-12-31 | 1.19M | +195.3% |
| FY2022 | 2022-12-31 | 403K | +189.9% |
| FY2021 | 2021-12-31 | 139K | — |
Stock-Based Compensation vs competitors
How CPH.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +64.7% is the 3rd highest of 8, against a peer median of -10.1%.
- Stock-based compensation amounts to 3.5% of revenue for CPH.TO, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$7.29M CAD | -36.7% | -24.4% | 2.3% | |
| LTM Mar 2026 | $7.23M USD | +54.8% | +18.6% | 14.1% | |
| LTM Mar 2026 | CA$6.84M CAD | +189.7% | +62.6% | 1.3% | |
| LTM Mar 2026 | CA$5.06M CAD | +220.3% | -44.8% | 1.6% | |
| LTM Mar 2026 | $4.38M USD | -55.0% | -25.6% | 1.7% | |
| LTM Mar 2026 | CA$3.45M CAD | -36.6% | — | 1.3% | |
| LTM Mar 2026 | CA$2.48M CAD | -10.1% | +21.0% | 89.8% | |
| LTM Mar 2026 | $1.8M USD | +64.7% | +62.8% | 3.5% | |
| Peer median (excluding CPH.TO) | — | -10.1% | -2.9% | 1.7% | |
Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.76M | 26.64M | 20.38M | 11.55M | 27.33M |
| Depreciation & Amortization | 701K | 989K | 1.23M | 4.02M | 7.23M |
| Deferred Income Tax | (114K) | (14.31M) | (2.74M) | (8.64M) | (10.36M) |
| Stock-Based Compensation | 139K | 403K | 1.19M | 1.07M | 1.74M |
| Change in Working Capital | 4.68M | (3.03M) | (3.28M) | 8.95M | 5.32M |
| Accounts Receivables | 2.56M | (144K) | 1.71M | (8.77M) | 2.7M |
| Inventory | (758K) | (502K) | (830K) | 3.6M | (2.44M) |
| Accounts Payables | (1.23M) | (1.45M) | 532K | 1.28M | 527.07K |
| Other Working Capital | 4.11M | (940K) | (4.69M) | 12.85M | 4.53M |
| Other Non-Cash Items | 652K | (109K) | (788K) | 2.6M | (1.01M) |
| Operating Cash Flow | 13.81M | 10.58M | 16M | 19.55M | 30.25M |
| Capital Expenditures | 0 | (81K) | (144K) | (44K) | (28.49K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 132.28K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (123K) | (80M) | 0 |
| Investing Cash Flow | 0 | (81K) | (144K) | (80.04M) | (72.24K) |
| Debt Repayment | (828K) | (56K) | (111K) | 39.79M | (35.61M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 218.76K |
| Common Stock Repurchased | (1.72M) | (1.99M) | (5.56M) | (176K) | (5.48M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 75K | 132K | 426K | (317K) | (311.36K) |
| Financing Cash Flow | (2.47M) | (1.91M) | (5.24M) | 39.3M | (41.18M) |
| Effect of Forex Changes | 62K | (292K) | 378K | (786K) | (194.92K) |
| Net Change in Cash | 11.41M | 8.29M | 10.99M | (21.99M) | (11.2M) |
| Free Cash Flow | 13.81M | 10.49M | 15.98M | 19.5M | 30.22M |
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
Intrinsic Alpha fair value
Locked
Current Price
$13.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.